HTG Medical Raises €450K in Pre-Seed Funding
HTG Medical has successfully secured €450,000 in a pre-seed funding round to advance its innovative medical technology. The company's flagship product, HTG Urogram, automates urine output monitoring with an impressive 97% accuracy, significantly reducing the workload of nurses by up to 60 minutes per shift. This technology has already proven its efficacy in Intensive Care Units (ICUs) and is poised for broader deployment.
Funding Details
The recent funding round was led by Garage Angels, with additional participation from Electron Capital Partners, JIC Ventures, Jinej fond, and Dendis Capital. This financial backing is expected to play a crucial role in the further development and distribution of HTG Medical's technology.
Strategic Use of Funds
The funds raised will be primarily directed towards enhancing the commercial rollout of HTG Urogram, which has already secured Medical Device Regulation (MDR) certification. This certification is a significant milestone, ensuring that the product meets rigorous European health and safety standards.
Market Impact
With the pre-seed investment, HTG Medical is well-positioned to expand the reach of its innovative urine monitoring system in hospitals across Europe. The automated system aims to streamline ICU operations, thereby improving patient care and efficiency in critical healthcare settings.
HTG Medical's commitment to improving healthcare efficiency through technology is evident in this latest funding round. The support from prominent investors underlines the potential impact and importance of their solutions in modern medical environments. As HTG Medical continues to innovate and expand, the healthcare industry can anticipate significant advancements in patient monitoring and care efficiency.
For more information about HTG Medical and its products, visit their website.